Stay updated with breaking news from Gerhard koenig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal biology and neuronal health to develop. ....
Arkuda seeks to disrupt the usual progression of neurodegenerative disease with medicines developed by applying cutting-edge knowledge from the domains of lysosomal and microglial biology. ....
/PRNewswire/ Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal and microglial biology to develop. ....
Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited form of dementia. If the biotech’s approach works, it could also have applications in other neurodegenerative conditions such as Alzheimer’s and Parkinson’s. ....